Regenicin, Inc. (RGIN)

Regenicin Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018
Selling, General & Admin	0.46	0.6	0.64	0.66	0.74	0.79
Research & Development	0.43	-	-	-	-	-
Operating Expenses	0.89	0.6	0.64	0.66	0.74	0.79
Operating Income	-0.89	-0.6	-0.64	-0.66	-0.74	-0.79
Interest Expense	-0.04	-0.04	-0.03	-0.05	-0.02	-0.02
Interest & Investment Income	0	-	-	-	-	-
EBT Excluding Unusual Items	-0.93	-0.64	-0.67	-0.71	-0.75	-0.81
Gain (Loss) on Sale of Investments	-0	-0	-0	-0	-0	-
Other Unusual Items	-	-	-	0.15	-	0.25
Pretax Income	-0.93	-0.64	-0.67	-0.56	-0.76	-0.56
Net Income	-0.93	-0.64	-0.67	-0.56	-0.76	-0.56
Preferred Dividends & Other Adjustments	0.05	0.05	0.07	0.07	0.07	0.07
Net Income to Common	-0.99	-0.69	-0.74	-0.63	-0.83	-0.63
Shares Outstanding (Basic)	153	153	153	153	153	153
Shares Outstanding (Diluted)	153	153	153	153	153	153
EPS (Basic)	-0.01	-0.00	-0.00	-0.00	-0.01	-0.00
EPS (Diluted)	-0.01	-0.00	-0.00	-0.00	-0.01	-0.00
EBIT	-0.89	-0.6	-0.64	-0.66	-0.74	-0.79

Source: S&P Global Market Intelligence. Standard template. Financial Sources.